Tianjin Chase Sun Pharmaceutical Co.

Tianjin, China

Tianjin Chase Sun Pharmaceutical Co.

Tianjin, China
SEARCH FILTERS
Time filter
Source Type

About Tianjin Chase Sun Pharmaceutical Co., Ltd. Tianjin Chase Sun Pharmaceutical Co., Ltd. ("Chase Sun") (300026.SZ) is one of China's 100 leading pharmaceutical companies by sales. Founded in 1996 and Headquartered in Tianjin City, China, Chase Sun is a group of companies with over 6,000 employees and net sales of RMB 3.9 billion in 2016, focusing on researching, developing, manufacturing and marketing of traditional Chinese medicine ("TCM"), synthetic drugs, biotech drugs and medical devices. The Company's common stock has been traded on Shenzhen GEM under ticker 300026 since October 2009. More information about Chase Sun can be found at www.chasesun.cn. About Hebron Technology Co., Ltd. Established in January 2005 and headquartered in Wenzhou City, Zhejiang Province, China, Hebron Technology Co., Ltd. ("Hebron" or the "Company") engages in research, development, and manufacture of highly specialized valves and pipe fitting products for use in the pharmaceutical, biological, food and beverage, and other clean industries. The Company also offers its customers comprehensive pipeline design, installation, construction, and ongoing maintenance services as holistic solution services. This press release contains information about Hebron's view of its future expectations, plans and prospects that constitute forward-looking statements. Actual results may differ materially from historical results or those indicated by these forward-looking statements as a result of a variety of factors including, but not limited to, risks and uncertainties associated with its ability to raise additional funding, its ability to maintain and grow its business, variability of operating results, its ability to maintain and enhance its brand, its development and introduction of new products and services, the successful integration of acquired companies, technologies and assets into its portfolio of products and services, marketing and other business development initiatives, competition in the industry, general government regulation, economic conditions, dependence on key personnel, the ability to attract, hire and retain personnel who possess the technical skills and experience necessary to meet the requirements of its clients, and its ability to protect its intellectual property. Hebron encourages you to review other factors that may affect its future results in Hebron's registration statement and in its other filings with the Securities and Exchange Commission. For more information, please contact: To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/hebron-technology-co-ltd-wins-bid-for-a-project-at-leading-pharmaceutical-company-in-tianjin-300462890.html


WENZHOU, China, May 24, 2017 /PRNewswire/ -- Hebron Technology Co., Ltd. ("Hebron" or the "Company") (Nasdaq: HEBT), a developer, manufacturer and installer of valves and pipe fittings for use in the pharmaceutical, biological, food and beverage, and other clean industries, today announced it has won a bid on the design and implementation of an oil-free compressed air pipe project (the "Project") at a pharmaceutical production facility owned by Tianjin Chase Sun Pharmaceutical Co., Ltd. ("Chase Sun"), a top 100 pharmaceutical company in China by sales with over 6,000 employees and over RMB 3.9 billion in annual sales. Mr. Anyuan Sun, Chairman and Chief Executive Officer of Hebron, commented, "Our winning bid for the Project speaks to the quality of our valve and pipe products and the reputation of our technical team in providing holistic production line solutions for leading pharmaceutical companies in China. We are excited about the opportunity to participate in Chase Sun's expansion projects and look forward to growing this relationship. Kudos to our marketing and technical teams for their dedicated and diligent efforts to make this happen." About Tianjin Chase Sun Pharmaceutical Co., Ltd. Tianjin Chase Sun Pharmaceutical Co., Ltd. ("Chase Sun") (300026.SZ) is one of China's 100 leading pharmaceutical companies by sales. Founded in 1996 and Headquartered in Tianjin City, China, Chase Sun is a group of companies with over 6,000 employees and net sales of RMB 3.9 billion in 2016, focusing on researching, developing, manufacturing and marketing of traditional Chinese medicine ("TCM"), synthetic drugs, biotech drugs and medical devices. The Company's common stock has been traded on Shenzhen GEM under ticker 300026 since October 2009. More information about Chase Sun can be found at www.chasesun.cn. About Hebron Technology Co., Ltd. Established in January 2005 and headquartered in Wenzhou City, Zhejiang Province, China, Hebron Technology Co., Ltd. ("Hebron" or the "Company") engages in research, development, and manufacture of highly specialized valves and pipe fitting products for use in the pharmaceutical, biological, food and beverage, and other clean industries. The Company also offers its customers comprehensive pipeline design, installation, construction, and ongoing maintenance services as holistic solution services. This press release contains information about Hebron's view of its future expectations, plans and prospects that constitute forward-looking statements. Actual results may differ materially from historical results or those indicated by these forward-looking statements as a result of a variety of factors including, but not limited to, risks and uncertainties associated with its ability to raise additional funding, its ability to maintain and grow its business, variability of operating results, its ability to maintain and enhance its brand, its development and introduction of new products and services, the successful integration of acquired companies, technologies and assets into its portfolio of products and services, marketing and other business development initiatives, competition in the industry, general government regulation, economic conditions, dependence on key personnel, the ability to attract, hire and retain personnel who possess the technical skills and experience necessary to meet the requirements of its clients, and its ability to protect its intellectual property. Hebron encourages you to review other factors that may affect its future results in Hebron's registration statement and in its other filings with the Securities and Exchange Commission. For more information, please contact: To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/hebron-technology-co-ltd-wins-bid-for-a-project-at-leading-pharmaceutical-company-in-tianjin-300462890.html


LONDON, UK / ACCESSWIRE / June 28, 2017 / Pro-Trader Daily takes a look at the latest corporate events and news making the headlines for Hebron Technology Co., Ltd (NASDAQ: HEBT), following which we have published a free report that can be viewed by signing up at http://protraderdaily.com/optin/?symbol=HEBT. The Company, which is a developer, manufacturer, and installer of valves and pipe fittings, announced on June 26, 2017, that it has signed a framework cooperation agreement to form a joint venture with Research and Product Complex BioPromin Ltd, a Ukraine-based Company specializing in noninvasive blood analyzing medical devices. For immediate access to our complimentary reports, including today's coverage, register for free now at: http://protraderdaily.com/register/. Discover more of our free reports coverage from other companies within the Diversified Machinery industry. Pro-TD has currently selected Actuant Corporation (NYSE: ATU) for due-diligence and potential coverage as the Company announced on June 21, 2017, its financial results for Q3 which ended on May 31, 2017. Tune in to our site to register for a free membership, and be among the early birds that get our report on Actuant when we publish it. At Pro-TD, we make it our mission to bring you news that matter about the stock you follow. Today, our research desk covers a blog story on HEBT; also brushing on ATU. Go directly to your stock of interest and access today's free coverage at: Subject to the terms of the agreement executed on June 16, 2017, both Hebron and BioPromin have agreed to develop, manufacture, and market BioPromin's proprietary noninvasive blood analyzing devices in China. The joint venture will be based in Konggang New Area, Longgang District, Wenzhou City, Zhejiang Province, with a registered capital of $5 million and a total investment of up to $50 million. According to the announcement, Hebron will own 80% of the Joint Venture, where BioPromin will hold the remaining 20% of the venture and the right of first refusal to acquire an additional 5% ownership in the venture from Hebron. Hebron views this agreement as a step to penetrate into the China's huge medical devices industry. Through the joint venture, the Company plans to integrate deep ties to the pharmaceutical industry and strong capabilities in manufacturing and marketing with BioPromin's innovative blood analyzing techniques. Hebron plans to bring BioPromin's clinically-proven blood analyzer products to the Chinese market, through this step. BioPromin's portfolio includes products like Automatic Noninvasive Express Screening Analyzer ("ANESA"), Noninvasive Hemogram Analyzer AMP, Low-Intensity Microwave and Decimeter Wave Therapy Apparatus "BIOL", and Star device. Hebron Technology deals in the development, manufacture, and delivery of customized installation of valves, and pipe fittings. It additionally offers pipeline design, installation, construction, and ongoing maintenance services. For the six month period, ended December 31, 2016, the Company reported that its net revenues surged 17.9% to $16.4 million, with revenues from installation services and fluid equipment sales increasing 19.7% and 5.9% respectively. Prior to the announcement, on March 10, 2017, the Company announced that it has entered into a non-binding Letter of Intent (LOI) pursuant to which Hebron acquired a majority equity interest in Shanghai Xinxiao Co., Ltd. Xinxiao currently operates one of the largest marketplaces for equipment and products used in the pharmaceutical, biological, chemical, food and beverage, and environmental industries. Hebron viewed this agreement as a definitive plan to expand its ecommerce business while leveraging the extensive database and strong relationships with leading Companies in the particular industry. On May 24, 2017, Hebron Technology announced that it has won a bid on the design and implementation of an oil-free compressed air pipe project at a pharmaceutical production facility, currently owned by Tianjin Chase Sun Pharmaceutical Co., Ltd. Chase Sun currently operates through its 6,000 employees and reported net annual sales of RMB 3.9 billion. This project was viewed as the development of Company's pharmaceutical product portfolio, as per the demand pertaining from the leading Pharmaceutical Companies in China. Hebron plans to leverage Chase Sun's expansion strategy to enhance the scale of its business and establish itself as the leading product manufacturer and deliver in the country. At the close of trading session on Tuesday, June 27, 2017, Hebron Technology's stock price rose 3.91% to end the day at $2.92. A total volume of 33.42 thousand shares were exchanged during the session. The Company's shares are trading at a PE ratio of 5.92. At Tuesday's closing price, the stock's net capitalization stands at $44.03 million. Pro-Trader Daily (Pro-TD) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. PRO-TD has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. PRO-TD has not been compensated; directly or indirectly; for producing or publishing this document. The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst, for further information on analyst credentials, please email contact@protraderdaily.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by PRO-TD. PRO-TD is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way. PRO-TD, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. PRO-TD, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, PRO-TD, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither PRO-TD nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://protraderdaily.com/disclaimer/. For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute. LONDON, UK / ACCESSWIRE / June 28, 2017 / Pro-Trader Daily takes a look at the latest corporate events and news making the headlines for Hebron Technology Co., Ltd (NASDAQ: HEBT), following which we have published a free report that can be viewed by signing up at http://protraderdaily.com/optin/?symbol=HEBT. The Company, which is a developer, manufacturer, and installer of valves and pipe fittings, announced on June 26, 2017, that it has signed a framework cooperation agreement to form a joint venture with Research and Product Complex BioPromin Ltd, a Ukraine-based Company specializing in noninvasive blood analyzing medical devices. For immediate access to our complimentary reports, including today's coverage, register for free now at: http://protraderdaily.com/register/. Discover more of our free reports coverage from other companies within the Diversified Machinery industry. Pro-TD has currently selected Actuant Corporation (NYSE: ATU) for due-diligence and potential coverage as the Company announced on June 21, 2017, its financial results for Q3 which ended on May 31, 2017. Tune in to our site to register for a free membership, and be among the early birds that get our report on Actuant when we publish it. At Pro-TD, we make it our mission to bring you news that matter about the stock you follow. Today, our research desk covers a blog story on HEBT; also brushing on ATU. Go directly to your stock of interest and access today's free coverage at: Subject to the terms of the agreement executed on June 16, 2017, both Hebron and BioPromin have agreed to develop, manufacture, and market BioPromin's proprietary noninvasive blood analyzing devices in China. The joint venture will be based in Konggang New Area, Longgang District, Wenzhou City, Zhejiang Province, with a registered capital of $5 million and a total investment of up to $50 million. According to the announcement, Hebron will own 80% of the Joint Venture, where BioPromin will hold the remaining 20% of the venture and the right of first refusal to acquire an additional 5% ownership in the venture from Hebron. Hebron views this agreement as a step to penetrate into the China's huge medical devices industry. Through the joint venture, the Company plans to integrate deep ties to the pharmaceutical industry and strong capabilities in manufacturing and marketing with BioPromin's innovative blood analyzing techniques. Hebron plans to bring BioPromin's clinically-proven blood analyzer products to the Chinese market, through this step. BioPromin's portfolio includes products like Automatic Noninvasive Express Screening Analyzer ("ANESA"), Noninvasive Hemogram Analyzer AMP, Low-Intensity Microwave and Decimeter Wave Therapy Apparatus "BIOL", and Star device. Hebron Technology deals in the development, manufacture, and delivery of customized installation of valves, and pipe fittings. It additionally offers pipeline design, installation, construction, and ongoing maintenance services. For the six month period, ended December 31, 2016, the Company reported that its net revenues surged 17.9% to $16.4 million, with revenues from installation services and fluid equipment sales increasing 19.7% and 5.9% respectively. Prior to the announcement, on March 10, 2017, the Company announced that it has entered into a non-binding Letter of Intent (LOI) pursuant to which Hebron acquired a majority equity interest in Shanghai Xinxiao Co., Ltd. Xinxiao currently operates one of the largest marketplaces for equipment and products used in the pharmaceutical, biological, chemical, food and beverage, and environmental industries. Hebron viewed this agreement as a definitive plan to expand its ecommerce business while leveraging the extensive database and strong relationships with leading Companies in the particular industry. On May 24, 2017, Hebron Technology announced that it has won a bid on the design and implementation of an oil-free compressed air pipe project at a pharmaceutical production facility, currently owned by Tianjin Chase Sun Pharmaceutical Co., Ltd. Chase Sun currently operates through its 6,000 employees and reported net annual sales of RMB 3.9 billion. This project was viewed as the development of Company's pharmaceutical product portfolio, as per the demand pertaining from the leading Pharmaceutical Companies in China. Hebron plans to leverage Chase Sun's expansion strategy to enhance the scale of its business and establish itself as the leading product manufacturer and deliver in the country. At the close of trading session on Tuesday, June 27, 2017, Hebron Technology's stock price rose 3.91% to end the day at $2.92. A total volume of 33.42 thousand shares were exchanged during the session. The Company's shares are trading at a PE ratio of 5.92. At Tuesday's closing price, the stock's net capitalization stands at $44.03 million. Pro-Trader Daily (Pro-TD) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. PRO-TD has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. PRO-TD has not been compensated; directly or indirectly; for producing or publishing this document. The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst, for further information on analyst credentials, please email contact@protraderdaily.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by PRO-TD. PRO-TD is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way. PRO-TD, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. PRO-TD, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, PRO-TD, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither PRO-TD nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://protraderdaily.com/disclaimer/. For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.


LONDON, UK / ACCESSWIRE / June 28, 2017 / Pro-Trader Daily takes a look at the latest corporate events and news making the headlines for Hebron Technology Co., Ltd (NASDAQ: HEBT), following which we have published a free report that can be viewed by signing up at http://protraderdaily.com/optin/?symbol=HEBT. The Company, which is a developer, manufacturer, and installer of valves and pipe fittings, announced on June 26, 2017, that it has signed a framework cooperation agreement to form a joint venture with Research and Product Complex BioPromin Ltd, a Ukraine-based Company specializing in noninvasive blood analyzing medical devices. For immediate access to our complimentary reports, including today's coverage, register for free now at: http://protraderdaily.com/register/. Discover more of our free reports coverage from other companies within the Diversified Machinery industry. Pro-TD has currently selected Actuant Corporation (NYSE: ATU) for due-diligence and potential coverage as the Company announced on June 21, 2017, its financial results for Q3 which ended on May 31, 2017. Tune in to our site to register for a free membership, and be among the early birds that get our report on Actuant when we publish it. At Pro-TD, we make it our mission to bring you news that matter about the stock you follow. Today, our research desk covers a blog story on HEBT; also brushing on ATU. Go directly to your stock of interest and access today's free coverage at: Subject to the terms of the agreement executed on June 16, 2017, both Hebron and BioPromin have agreed to develop, manufacture, and market BioPromin's proprietary noninvasive blood analyzing devices in China. The joint venture will be based in Konggang New Area, Longgang District, Wenzhou City, Zhejiang Province, with a registered capital of $5 million and a total investment of up to $50 million. According to the announcement, Hebron will own 80% of the Joint Venture, where BioPromin will hold the remaining 20% of the venture and the right of first refusal to acquire an additional 5% ownership in the venture from Hebron. Hebron views this agreement as a step to penetrate into the China's huge medical devices industry. Through the joint venture, the Company plans to integrate deep ties to the pharmaceutical industry and strong capabilities in manufacturing and marketing with BioPromin's innovative blood analyzing techniques. Hebron plans to bring BioPromin's clinically-proven blood analyzer products to the Chinese market, through this step. BioPromin's portfolio includes products like Automatic Noninvasive Express Screening Analyzer ("ANESA"), Noninvasive Hemogram Analyzer AMP, Low-Intensity Microwave and Decimeter Wave Therapy Apparatus "BIOL", and Star device. Hebron Technology deals in the development, manufacture, and delivery of customized installation of valves, and pipe fittings. It additionally offers pipeline design, installation, construction, and ongoing maintenance services. For the six month period, ended December 31, 2016, the Company reported that its net revenues surged 17.9% to $16.4 million, with revenues from installation services and fluid equipment sales increasing 19.7% and 5.9% respectively. Prior to the announcement, on March 10, 2017, the Company announced that it has entered into a non-binding Letter of Intent (LOI) pursuant to which Hebron acquired a majority equity interest in Shanghai Xinxiao Co., Ltd. Xinxiao currently operates one of the largest marketplaces for equipment and products used in the pharmaceutical, biological, chemical, food and beverage, and environmental industries. Hebron viewed this agreement as a definitive plan to expand its ecommerce business while leveraging the extensive database and strong relationships with leading Companies in the particular industry. On May 24, 2017, Hebron Technology announced that it has won a bid on the design and implementation of an oil-free compressed air pipe project at a pharmaceutical production facility, currently owned by Tianjin Chase Sun Pharmaceutical Co., Ltd. Chase Sun currently operates through its 6,000 employees and reported net annual sales of RMB 3.9 billion. This project was viewed as the development of Company's pharmaceutical product portfolio, as per the demand pertaining from the leading Pharmaceutical Companies in China. Hebron plans to leverage Chase Sun's expansion strategy to enhance the scale of its business and establish itself as the leading product manufacturer and deliver in the country. At the close of trading session on Tuesday, June 27, 2017, Hebron Technology's stock price rose 3.91% to end the day at $2.92. A total volume of 33.42 thousand shares were exchanged during the session. The Company's shares are trading at a PE ratio of 5.92. At Tuesday's closing price, the stock's net capitalization stands at $44.03 million. Pro-Trader Daily (Pro-TD) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. PRO-TD has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. PRO-TD has not been compensated; directly or indirectly; for producing or publishing this document. The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst, for further information on analyst credentials, please email [email protected]. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by PRO-TD. PRO-TD is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way. PRO-TD, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. PRO-TD, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, PRO-TD, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither PRO-TD nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://protraderdaily.com/disclaimer/. For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.


Ding J.,Fudan University | Li Q.-Y.,Fudan University | Wang X.,Fudan University | Sun C.-H.,Tianjin Chasesun Pharmaceutical Co. | And 2 more authors.
Journal of Neurochemistry | Year: 2010

Rho kinase (ROCK) may play an important role in regulating biological events of cells, including proliferation, differentiation and survival/death. Blockade of ROCK promotes axonal regeneration and neuron survival in vivo and in vitro, thereby exhibiting potential clinical applications in spinal cord damage and stroke. Our previous studies have demonstrated that Fasudil, a selective ROCK inhibitor, induced neuroprotection in vitro. Here we used an in vivo model of hypoxia/reoxygenation (H/R) injury to examine the neuroprotective effect of Fasudil, and explore its possible mechanism(s) in vivo. H/R resulted in the loss of hippocampal neurons, accompanied by increased apoptosis of neurons in hippocampus. The expression of ROCK II and activity of ROCK in the brain were increased after H/R, and located only in microglia, but not in astrocytes and neurons. The administration of Fasudil inhibited the activity of ROCK in brain tissue and cultured microglia, and protected hippocampal neurons against H/R injury. Further immunohistochemical analysis and cytokine determination revealed that Fasudil inhibited inducible nitric oxide synthase immunoreactivity in microglia and pro-inflammatory factors in brain tissue after H/R, which is consistent with the observation wherein Fasudil reduced the pro-inflammatory factors nitric oxide, IL-1β, IL-6 and TNF-α, and increased anti-inflammatory factor IL-10 in cultured microglia under normoxic or hypoxic conditions. Our results indicate that inhibition of ROCK by Fasudil may represent a useful therapeutic perspective by inhibiting microglial inflammatory responses in the CNS. © 2010 International Society for Neurochemistry.


Ye H.,Nankai University | Liu R.,Nankai University | Li D.,Nankai University | Liu Y.,Nankai University | And 7 more authors.
Organic Letters | Year: 2013

A facile approach to the diazotransfer reagent of imidazole-1-sulfonyl azide was reported. The procedure was well optimized to clarify potential explosion risks. A high production yield as well as small batch variation was achieved even without careful pretreatment of reagents and solvents. HPLC and NMR methods to monitor the process were provided. These features made this protocol suitable for large scale preparation in academia and industry as well. © 2012 American Chemical Society.


Patent
Tianjin Chasesun Pharmaceutical Co. and Third Military Medical University | Date: 2011-03-21

The use of Kukoamine A and Kukoamine B in the preparation of drugs for the prevention and treatment of sepsis and autoimmune disease is disclosed. Bacterial endotoxin/lipopolysaccaride (LPS) and unmethylated DNA (CpG DNA) of bacteria, the major pathogen-associated molecular patterns in sepsis and autoimmune disease, are specifically targeted, while the disclosed use directionally isolates lead compounds from traditional Chinese medicine. These measures can overcome the major defects of uncertainty of pharmacological material basis and drug targets of extracts and constituents of traditional Chinese medicine. The disclosed use can help in developing a safe, effective and quality controllable drug for prevention and treatment of sepsis and autoimmune disease so as to help solve the present lack of effective drugs in clinical treatment.


Patent
Third Military Medical University and Tianjin Chasesun Pharmaceutical Co. | Date: 2013-09-18

Provided are salts of kukoamine B, their preparation method and their use in preventing and treating sepsis diseases.


Patent
Third Military Medical University and Tianjin Chasesun Pharmaceutical Co. | Date: 2013-05-15

Use of kukoamine A and kukoamine B in preparing medicine for preventing and treating sepsis and autoimmune diseases. The kukoamine A and kukoamine B are extracted from cortex lycii radicis. The medicine is used for antagonism of bacterial endotoxin (LPS) and bacteria non-methylated DNA (CpG DNA).


Patent
Tianjin Chasesun Pharmaceutical Co. | Date: 2011-03-21

Salts of kukoamine B, their preparation method and their pharmaceutical use in preparation of drugs for preventing and treating sepsis. Experiments indicate that salts of kukoamine B have a good effect on antagonizing the key factors inducing sepsis, and can be used in the preparation of drugs for preventing and treating sepsis. Under the current circumstances of the lack of effective measures for the treatment of sepsis in clinical practice, the medicinal formulations, which comprise the salts of kukoamine B, pharmaceutically acceptable carrier and/or diluent, provide a new approach for the prevention and treatment of sepsis.

Loading Tianjin Chase Sun Pharmaceutical Co. collaborators
Loading Tianjin Chase Sun Pharmaceutical Co. collaborators